# US 2003/0216443 A1 · Pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216443 A1
- Document ID: US20030216443A1
- Status: Published application
- Kind: A1
- Application number: 10/462,793
- Filed: 2003-06-17
- Published: 2003-11-20
- Earliest claimed: 1995-06-20
- Assignees: Takeda Chemical Industries, Ltd.
- Inventors: Hitoshi Ikeda; Takashi Sohda; Hiroyuki Odaka
- Web page: https://patentgrep.com/patent/US20030216443A1

## CPC

- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/415: 1,2-Diazoles
- A61K 31/42: Oxazoles
- A61K 31/4245: Oxadiazoles
- A61K 31/425: Thiazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/52: Purines, e.g. adenine
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/48: of the pancreatic hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

## Claims

### Claim 1

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with at least one member of the group consisting of an α-glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a statin compound, a squalene synthesis inhibitor, a fibrate compound, a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor.

### Claim 2 (depends on 1)

Pharmaceutical composition according to claim 1, wherein the insulin sensitivity enhancer is a compound represented by the formula:
8
wherein R represents an optionally substituted hydrocarbon or heterocyclic group; Y represents a group represented by —CO—, —CH(OH)— or —NR3— (wherein R3 represents an optionally substituted alkyl group); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a C1-7 divalent aliphatic hydrocarbon group; Q represents oxygen atom or sulfur atom; R1 represents hydrogen atom or an alkyl group; ring E may optionally have further 1 to 4 substituents, and the substituents may optionally be combined with R1 to form a ring; L and M respectively represent hydrogen atom, or L and M may optionally be combined with each other to form a bond; or a pharmacologically acceptable salt thereof.

### Claim 3 (depends on 1)

Pharmaceutical composition according to claim 1, wherein R is an optionally substituted heterocyclic group.

### Claim 4 (depends on 1)

Pharmaceutical composition according to claim 1, wherein m is 0.

### Claim 5 (depends on 1)

Pharmaceutical composition according to claim 1, wherein X is CH.

### Claim 6 (depends on 1)

Pharmaceutical composition according to claim 1, wherein R1 is hydrogen atom.

### Claim 7 (depends on 1)

Pharmaceutical composition according to claim 1, wherein the partial formula:
9
wherein R2 represents hydrogen atom, an alkyl group, an optionally substituted hydroxyl group, a halogen atom, an optionally substituted acyl group, vitro group or an ioptionally substituted amino group.

### Claim 8 (depends on 1)

Pharmaceutical composition according to claim 1, wherein L and M are hydrogen atom.

### Claim 9 (depends on 1)

Pharmaceutical composition according to claim 1, wherein R is pyridyl, oxazolyl or thiazolyl group optionally having 1 to 3 substituents selected from C1-3 alkyl, furyl, thienyl, phenyl and naphthyl; m is 0; n is 0 or 1; X is CH; A is a bond or —(CH2)2—; R1 is hydrogen atom; the partial formula:
10
and R2 is hydrogen atom or C1-4 alkoxy group; and L and M are both hydrogen atom.

### Claim 10 (depends on 2)

Pharmaceutical composition according to claim 2, wherein the compound represented by the formula (I) is pioglitazone.

### Claim 11 (depends on 1)

Pharmaceutical composition according to claim 1, which comprises an insulin sensitivity enhancer in combination with an α-glucosidase inhibitor.

### Claim 12 (depends on 11)

Pharmaceutical composition according to claim 11, wherein the α-glucosidase inhibitor is voglibose.

### Claim 13 (depends on 11)

Pharmaceutical composition according to claim 11, wherein the insulin sensitivity enhancer is pioglitazone and the α-glucosidase inhibitor is voglibose.

### Claim 14 (depends on 1)

Pharmaceutical composition according to claim 1, which is for prophylaxis or treatment of diabetes.

### Claim 15

Pharmaceutical composition which comprises a compound represented by the formula:
11
wherein R′ represents an optionally substituted hydrocarbon or heterocyclic group; Y represents a group represented by —CO—, —CH(OH)— or —NR3— (wherein R3 represents an optionally substituted alkyl group); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a C1-7 divalent aliphatic hydrocarbon group; Q represents oxygen atom or sulfur atom; R1 represents hydrogen atom or an alkyl group; ring E may optionally have further 1 to 4 substituents, and the substituents may optionally be combined with R1 to form a ring; L and M respectively represent hydrogen atom, or L and M may optionally be combined with each other to form a bond; with a proviso that R′ does not represent benzopyranyl group when m and n are O, X represents CH, A represents a bond, Q represents sulfur atom, R1, L and M represent hydrogen atom and ring E does not have further substituents; or a pharmacologically acceptable salt thereof in combination with an insulin secretion enhancer and/or an insulin preparation.

### Claim 16 (depends on 15)

Pharmaceutical composition according to claim 15, wherein R′ is an optionally substituted heterocyclic group.

### Claim 17 (depends on 15)

Pharmaceutical composition according to claim 15, wherein m is 0.

### Claim 18 (depends on 15)

Pharmaceutical composition according to claim 15, wherein X is CH.

### Claim 19 (depends on 15)

Pharmaceutical composition according to claim 15, wherein R1 is hydrogen atom.

### Claim 20 (depends on 15)

Pharmaceutical composition according to claim 15, wherein the partial formula:
12
wherein R2 represents hydrogen atom, an alkyl group, an optionally substituted hydroxyl group, a halogen atom, an optionally substituted acyl group, nitro group or an optionally substituted amino group.

### Claim 21 (depends on 15)

Pharmaceutical composition according to claim 15, wherein L and M are hydrogen atom.

### Claim 22 (depends on 15)

Pharmaceutical composition according to claim 15, wherein R′ is pyridyl, oxazolyl or thiazolyl group optionally having 1 to 3 substituents selected from C1-3 alkyl, furyl, thienyl, phenyl and naphthyl; m is 0; n is 0 or 1; X is CH; A is a bond or —(CH2)2—; R1 is hydrogen atom; the partial formula:
13
and R2 is hydrogen atom or C1-4 alkoxy group; and L and M are both hydrogen atom.

### Claim 23 (depends on 15)

Pharmaceutical composition according to claim 15, wherein the compound represented by the formula (II) is the compound represented by the formula:
14

### Claim 24 (depends on 15)

Pharmaceutical composition according to claim 15, wherein the compound represented by the formula (II) is pioglitazone.

### Claim 25 (depends on 15)

Pharmaceutical composition according to claim 15, wherein the insulin secretion enhancer is glibenclamide.

### Claim 26 (depends on 15)

Pharmaceutical composition according to claim 15, wherein the compound represented by the formula (II) is pioglitazone and the insulin secretion enhancer is glibenclamide.

### Claim 27 (depends on 15)

Pharmaceutical composition according to claim 15, which is for prophylaxis or treatment of diabetes.

### Claim 28 (depends on 1)

Method for treating diabetes in a mammal in need thereof, which comprises administering such mammal a therapeutically effective amount of a pharmaceutical composition as defined in claim 1.

### Claim 29 (depends on 15)

Method for treating diabetes in a mammal in need thereof, which comprises administering such mammal a therapeutically effective amount of a pharmaceutical composition as defined in claim 15.
